A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis

Trial Profile

A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs BIIB 023 (Primary)
  • Indications Lupus nephritis
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 14 Apr 2016 This trial is prematurely ended in Belgium, Spain, Germany, Italy (end date: 8 Oct 2015), Poland (end date: 8 Oct 2015) and completed in Hungary ( 15 Jan 2016).
    • 26 Oct 2015 Planned End Date changed from 1 Jan 2019 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 26 Oct 2015 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top